亚洲乳腺癌的TP53体细胞突变与亚型特异性效应相关。

Mohana Eswari Ragu, Joanna Mei Ch'wan Lim, Pei-Sze Ng, Cheng-Har Yip, Pathmanathan Rajadurai, Soo-Hwang Teo, Jia-Wern Pan
{"title":"亚洲乳腺癌的TP53体细胞突变与亚型特异性效应相关。","authors":"Mohana Eswari Ragu,&nbsp;Joanna Mei Ch'wan Lim,&nbsp;Pei-Sze Ng,&nbsp;Cheng-Har Yip,&nbsp;Pathmanathan Rajadurai,&nbsp;Soo-Hwang Teo,&nbsp;Jia-Wern Pan","doi":"10.1186/s13058-023-01635-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Recent genomics studies of breast cancer in Asian cohorts have found a higher prevalence of TP53 mutations in Asian breast cancer patients relative to Caucasian patients. However, the effect of TP53 mutations on Asian breast tumours has not been comprehensively studied.</p><p><strong>Methods: </strong>Here, we report an analysis of 492 breast cancer samples from the Malaysian Breast Cancer cohort where we examined the impact of TP53 somatic mutations in relation to PAM50 subtypes by comparing whole exome and transcriptome data from tumours with mutant and wild-type TP53.</p><p><strong>Results: </strong>We found that the magnitude of impact of TP53 somatic mutations appears to vary between different subtypes. TP53 somatic mutations were associated with higher HR deficiency scores as well as greater upregulation of gene expression pathways in luminal A and luminal B tumours compared to the basal-like and Her2-enriched subtypes. The only pathways that were consistently dysregulated when comparing tumours with mutant and wild-type TP53 across different subtypes were the mTORC1 signalling and glycolysis pathways.</p><p><strong>Conclusion: </strong>These results suggest that therapies that target TP53 or other downstream pathways may be more effective against luminal A and B tumours in the Asian population.</p>","PeriodicalId":9283,"journal":{"name":"Breast Cancer Research : BCR","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134541/pdf/","citationCount":"2","resultStr":"{\"title\":\"TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects.\",\"authors\":\"Mohana Eswari Ragu,&nbsp;Joanna Mei Ch'wan Lim,&nbsp;Pei-Sze Ng,&nbsp;Cheng-Har Yip,&nbsp;Pathmanathan Rajadurai,&nbsp;Soo-Hwang Teo,&nbsp;Jia-Wern Pan\",\"doi\":\"10.1186/s13058-023-01635-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Recent genomics studies of breast cancer in Asian cohorts have found a higher prevalence of TP53 mutations in Asian breast cancer patients relative to Caucasian patients. However, the effect of TP53 mutations on Asian breast tumours has not been comprehensively studied.</p><p><strong>Methods: </strong>Here, we report an analysis of 492 breast cancer samples from the Malaysian Breast Cancer cohort where we examined the impact of TP53 somatic mutations in relation to PAM50 subtypes by comparing whole exome and transcriptome data from tumours with mutant and wild-type TP53.</p><p><strong>Results: </strong>We found that the magnitude of impact of TP53 somatic mutations appears to vary between different subtypes. TP53 somatic mutations were associated with higher HR deficiency scores as well as greater upregulation of gene expression pathways in luminal A and luminal B tumours compared to the basal-like and Her2-enriched subtypes. The only pathways that were consistently dysregulated when comparing tumours with mutant and wild-type TP53 across different subtypes were the mTORC1 signalling and glycolysis pathways.</p><p><strong>Conclusion: </strong>These results suggest that therapies that target TP53 or other downstream pathways may be more effective against luminal A and B tumours in the Asian population.</p>\",\"PeriodicalId\":9283,\"journal\":{\"name\":\"Breast Cancer Research : BCR\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134541/pdf/\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer Research : BCR\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s13058-023-01635-2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research : BCR","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13058-023-01635-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

背景:最近的亚洲乳腺癌基因组学研究发现,亚洲乳腺癌患者中TP53突变的发生率高于高加索患者。然而,TP53突变对亚洲乳腺肿瘤的影响尚未得到全面的研究。方法:在这里,我们报告了来自马来西亚乳腺癌队列的492例乳腺癌样本的分析,我们通过比较突变型和野生型TP53肿瘤的全外显子组和转录组数据,研究了TP53体细胞突变对PAM50亚型的影响。结果:我们发现TP53体细胞突变的影响程度在不同亚型之间有所不同。与基底样和her2富集亚型相比,TP53体细胞突变与腔内A和腔内B肿瘤中较高的HR缺乏评分以及更大的基因表达途径上调相关。当将肿瘤与突变型和野生型TP53在不同亚型中进行比较时,唯一一致失调的途径是mTORC1信号传导和糖酵解途径。结论:这些结果表明,针对TP53或其他下游途径的治疗可能对亚洲人群的管腔A和B肿瘤更有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects.

TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects.

TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects.

TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects.

Background: Recent genomics studies of breast cancer in Asian cohorts have found a higher prevalence of TP53 mutations in Asian breast cancer patients relative to Caucasian patients. However, the effect of TP53 mutations on Asian breast tumours has not been comprehensively studied.

Methods: Here, we report an analysis of 492 breast cancer samples from the Malaysian Breast Cancer cohort where we examined the impact of TP53 somatic mutations in relation to PAM50 subtypes by comparing whole exome and transcriptome data from tumours with mutant and wild-type TP53.

Results: We found that the magnitude of impact of TP53 somatic mutations appears to vary between different subtypes. TP53 somatic mutations were associated with higher HR deficiency scores as well as greater upregulation of gene expression pathways in luminal A and luminal B tumours compared to the basal-like and Her2-enriched subtypes. The only pathways that were consistently dysregulated when comparing tumours with mutant and wild-type TP53 across different subtypes were the mTORC1 signalling and glycolysis pathways.

Conclusion: These results suggest that therapies that target TP53 or other downstream pathways may be more effective against luminal A and B tumours in the Asian population.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信